Literature DB >> 9332511

Mycobacterium xenopi infection in patients with human immunodeficiency virus infection.

P el-Helou1, A Rachlis, I Fong, S Walmsley, A Phillips, I Salit, A E Simor.   

Abstract

Mycobacterium xenopi is one of the most frequently isolated nontuberculous mycobacteria in Ontario, Canada. We reviewed the records of 28 human immunodeficiency virus (HIV)-infected patients from whom M. xenopi was isolated between 1982 and 1995. M. xenopi was recovered from respiratory specimens from 24 patients, most of whom had clinical and radiographic evidence of pulmonary disease. However, coexistent pulmonary infection due to other pathogens was found in 17 patients: Pneumocystis carinii (9 patients), cytomegalovirus (5), Haemophilus influenzae (2), Mycobacterium avium complex (2), Streptococcus pneumoniae (1), Staphylococcus aureus (1), Aspergillus species (1), and Histoplasma capsulatum (1). Three patients had bacteremia with M. xenopi, including two patients with pulmonary infection. Two of the bacteremic patients had chronic fever and a wasting syndrome. Twenty-one (75%) of the 28 patients were thought to be colonized, and seven patients (25%; of whom four had CD4 cell counts of < or = 50/mm3) were thought to have significant infection due to M. xenopi. Sixteen patients died, but in no case was death attributable to M. xenopi infection. In a region where M. xenopi is a relatively common mycobacterial isolate, the organism frequently colonizes HIV-infected patients. Significant disease occurs in those patients with more advanced HIV infection.

Entities:  

Mesh:

Year:  1997        PMID: 9332511     DOI: 10.1086/514525

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Low dose inhaled corticosteroids and the prevention of death from asthma.

Authors:  J C Kips; R A Pauwels
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Pleuritis due to Mycobacterium xenopi without pulmonary infection.

Authors:  Keren Bachar; Tiberiu Shulimzon; Efrat Ofek; Michael J Segel
Journal:  Access Microbiol       Date:  2022-03-22

3.  Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

Authors:  N Lounis; C Truffot-Pernot; A Bentoucha; J Robert; B Ji; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Spondylitis due to Mycobacterium xenopi in a human immunodeficiency virus type 1-infected patient: case report and review of the literature.

Authors:  Agnès Meybeck; Claude Fortin; Sophie Abgrall; Homa Adle-Biassette; Gilles Hayem; Raymond Ruimy; Patrick Yeni
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Pulmonary Mycobacterium xenopi infection in AIDS patients treated with HAART in Hungary.

Authors:  J Szlávik; C Sárvári
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-14       Impact factor: 3.267

Review 6.  Other HIV-associated pneumonias.

Authors:  Jakrapun Pupaibool; Andrew H Limper
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

7.  Mycobacterium xenopi: Evidence for Increased Rate of Clinical Isolation.

Authors:  Martin H Bluth; Ramon Vera; Jafar Razeq; Martin Kramer; Khaled I Abu-Lawi
Journal:  Int J Biomed Sci       Date:  2009-06

Review 8.  Histoplasmosis in Children; HIV/AIDS Not a Major Driver.

Authors:  Bassey E Ekeng; Kevin Edem; Ikechukwu Amamilo; Zachary Panos; David Denning; Rita O Oladele
Journal:  J Fungi (Basel)       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.